As PCA3 increases with cancer aggressiveness, tests based on it—Progensa PCA3, MiPS and ExoDx—show the ability to distinguish between cancers with high and low Gleason scores, indicating high utility in therapeutic decision-making. Here, PCA3 is linked to cancer.